

STEPP **KESSLER, GOLDSTEIN & FOX** L.L.C.

ATTORNEYS AT LAW

100 NEW YORK AVENUE N.W. • WASHINGTON, D.C. 20005-3934

PHONE (202) 371-2600 • FAX (202) 371-2640 • WWW.KGFLAW.COM

j1003 U.S.
09/25/01

09/25/01
j1011 U.S. PTO
09/25/01

ROBERT GREENE SPERNE
EDWARD J. KESSLER
DOROTHY GOLDSTEIN
JAMES L. FOX**
DAVID K. CORNWELL
ROBERT W. EDMOND
TRACY GENE G. BURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
FRANK STEFFE
MICHAEL O. JEFF
STEVEN R. TUDWIG

JOHN M. COLEMAN
JUDY E. ALDRICH
ROBERT MILLION, III
MICHAEL J. MESSINGER
JUDITH A. KIM
T. MICHAEL FERA, JR.
PATRICK E. GARRETT
JEFFREY T. MELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
PATRICK D. PIEREN
LAWRENCE B. BUGAS SKY
CRYSTAL D. FAYLES

EDWARD W. YEE
ALBERT L. FERRARI
DONALD R. BANWELL
PETER A. JAKIMAN
MOLLY A. MCALL
TERESA J. MEDLER
JEFFREY S. NEAVER
KENNETH P. PATTERSON
DONALD J. FEATHERSTONE
VINCENT G. CARVANO
JOHN A. MARRONI*
ALBERT J. FARNOL III
ELIZABETH HUN FORD

A. RUSSELL SWINDELL
THOMAS C. PALA
BRIAN J. DEE BURG*
J. ROLLO REASTON*
RYAN J. STAMPER*
REGINALD O. LUCAS*
THEODORE A. WOOD
ELIZABETH J. HAANE
BRUCE S. CHALKER
KAREN R. MARKOWICZ**
SUZANNE E. ZSKA**
ANDREA J. KAMAGE**
NANCY J. LEETH**

MARY R. TERRY**
JOSEPH M. CONRAD**
DOLPHUS M. WILSON**
ANNE E. SUMMERS ELLIS**
SANTHA M. BOCHEZ**
HELENE C. CARLSON**
BABY J. LONGSWORTH**
JUSTIN T. JOHNSON**
MATTHEW J. DOWD**
T. MOTHY M. SPEER**
AARON L. SCHWARTZ**

**LITIGATE TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

September 25, 2001

WRITER'S DIRECT NUMBER:
(202) 371-2589

INTERNET ADDRESS:
LARRYB@SKGE.COM

BOX PATENT APPLICATION

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
Appl. No. *To be assigned*; Filed: Herewith

For: **Model for Neurodegenerative Diseases Involving Amyloid
Accumulation**

Inventors: *Lynch et al.*

Our Ref: 1819.0040001/MAC/LBB

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office:

1. USPTO Utility Patent Application Transmittal Form PTO/SB/05 (*in
duplicate*);
2. U.S. Utility Patent Application entitled:

**MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING
AMYLOID ACCUMULATION**

and naming as inventors:

Gary LYNCH
Xiaoning BI
Christine M. GALL

Commissioner for Patents
September 25, 2001
Page 2

the application comprising:

- a. specification containing:
 - i. 61 pages of description prior to the claims;
 - ii. 11 pages of claims (78 claims);
 - iii. a one (1) page abstract;
- b. 7 sheets of drawings: (Figures: 1, 2, 3, 4, 5, 6 and 7); and
- c. an Application Data Sheet (37 C.F.R. § 1.76).

3. 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time (*in duplicate*); and
4. Two (2) return postcards.

The name of the assignee is **The Regents of the University of California**.


Correspondence should be sent to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

LBB/ybh

P:\USERS\YHARRIS\BB\P10\181941skgtapp1.t
SKGP Rec. 2 13 01 mac



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
OMB Control Number 0651-0032

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.	1819.0040001/MAC/LBB
First Inventor	LYNCH, et al.
Title	MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. Applicant claims small entity status.
See 37 CFR 1.27.

3. Specification [Total Pages 73]
(preferred arrangement set forth below)
 Descriptive title of the Invention
 Cross Reference to Related Applications
 Statement Regarding Fed sponsored R & D
 Reference to sequence listing, a table, or a computer program listing appendix
 Background of the Invention
 Brief Summary of the Invention
 Brief Description of the Drawings (if filed)
 Detailed Description
 Claims
 Abstract of the Disclosure

4. Drawing(s) (35 U.S.C. 113) [Total Sheets 7]

5. Oath or Declaration [Total Pages 1]
a. Newly executed (original or copy)
b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76.

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
a. Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. CD-ROM or CD-R (2 copies); or
ii. paper
c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))

10. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)

11. English Translation Document (if applicable)

12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

17. Other: Authorization under 37 C.F.R. § 1.136(a)(3)
 Other: The name of the assignee is: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-Part (CIP)
Prior application information: Examiner _____ of prior application No: _____ / _____
Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label

Customer No. 26111

or Correspondence address below

(Insert Customer No. 26111 or attach bar code label here)

NAME	STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C. / PATENT & TRADEMARK OFFICE Attorneys at Law		
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	

NAME (Print/Type)	Lawrence B. Bugalsky	Registration No. (Attorney/Agent)	35,086
SIGNATURE	<i>Lawrence B. Bugalsky</i>		
Date	September 25, 2007		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

J1011 U.S. PTO
09/961381
09/25/01

In re application of:

LYNCH *et al.*

Appl. No. *To be assigned*

Filed: Herewith

For: **Model for Neurodegenerative
Diseases Involving Amyloid
Accumulation**

Confirmation No. *To be assigned*

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1819.0040001/MAC/LBB

**Authorization To Treat A Reply As Incorporating An Extension Of
Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner for Patents
Washington, D.C. 20231

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply. A duplicate copy of this authorization is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

Date: September 25, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600